107 results about "Umbilical Cord Blood Stem Cell" patented technology

The invention discloses a stem cell culture medium, an application of the stem cell culture medium and a stem cell cultivation method. Blood serum does not exist in the stem cell culture medium. The stem cell culture medium comprises amino acid, vitamin, salt, lipoid, cytokines and egg white polypeptide. The stem cell culture medium is suitable for fast cultivating stem cells which are tissue sources of human and mammal, and comprises but not is limited by fat mesenchyme stem cells, mesenchymal stem cells and umbilical cord blood stem cells. The culture medium enables increasing speed of the cells to be improved by 3-5 times, and differential potentials of the cells can not be affected. Compared with an ordinary stem cell culture medium, stem cells from different sources can be fast expanded, passage number is prolonged, and proficiency properties of the stem cells can be well kept.

The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.

This invention is concerned with stem cells derived from umbilical cord blood serum and a method for growing human embryonic stem cells and adult cells comprising sera separated from clotted umbilical cord blood, including growing and differentiating cord blood stem cells into neural precursors, comprising transdifferentiating CD34+ stem cells from mononuclear cells derived from umbilical cord blood to neural precursors. The stem cells obtained from the umbilical cord include pluripotent stem and progenitor cell population of mononuclear cells, and separating pluripotent stem and progenitor cell population of mononuclear cells obtained from the umbilical cord blood. A magnetic cell separator is used to separate out cells which contain a CD marker and then expanding the cells in a growth medium containing retinoic acid and one or more growth factors BDNF, GDNF, NGF and FGF as a differentiating agent. The invention is also concerned with the transplantation and repair of nerve damage, stokes, spinal injury, Parkinson's and Alzheimer's, prepared in accordance with the aforesaid method and a media for culturing umbilical cord blood stem calls consisting essentially of cord blood stem cells derived from umbilical cord blood serum.

The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high yield by treatment with dithiothreitol (DTT) and a low concentration of trypsin and culturing the amniotic epithelial cells in a medium containing a Rho-associated kinase inhibitor. The human amniotic epithelial cell-derived stem cells are easily extracted compared to existing therapeutic stem cells such as umbilical cord blood stem cells and bone marrow stem cells, the yield and proliferation thereof are significantly increased by DTT treatment, the addition of the ROCK inhibitor or the replacement of medium. Thus, the method can be used to efficiently prepare adult stem cells.

The present invention relates to a reagent kit of the isolation of a bone marrow umbilical cord blood stem cell in vitro and the application method thereof. The present invention is characterized in that Lin antibody red blood cell precipitant cell preserving solution, and sodium iothalamate-polysucrose 400 ^{# or HISTOPAQUE1077 or Ficoll are contained in the reagent kit, and each reagent solution is preserved dividually. The present invention adopts the method which combines a negative collection method and a density method, thus the surface of the stem cell which is collected and abstracted has no any label, the cells which are isolated and abstracted are Lin antigenic negative cells, the method is simple, and the present invention can be directly used to isolate and abstract the stem cells clinically. The reagent kit of the present invention can operate the industrialized production, to realize the promotion of the isolation and purification technology of the human hematopoietic stem cell, leading the doctor to conveniently cure the patient with the stem cells like the medicine usage.}

The present invention is related generally to embryonic-like stem cells isolated from human umbilical cord blood, designated herein as cord blood-stem cells (CB-SC's), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to multiple types of cells. In addition, the CB-SC display low immunogenicity and immune regulation. These cells are, therefore, suitable for use in stem cell-based therapies for the treatment of diseases such as Parkinson's disease, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects, and for preventing, treating and/or reducing an autoimmune disease in a mammalian subject.

The invention relates to a medical dressing with bioactivity and a preparation method of the medical dressing and belongs to the technical field of biomedical engineering and material science. The medical dressing with the bioactivity is used for covering skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repair and is prepared as follows: one or more of embryonic stem cells, umbilical cord blood stem cells, amniotic fluid stem cells, peripheral blood stem cells and bone mesenchymal stem cells of humans or animals are cultured in vitro, stem cell growth factors secreted in the logarithmic growth phase are collected and mixed in proportion with one or more of I type collagen, III type collagen, chitosan, hyaluronic acid, chondroitin sulfate and sodium alginate, thin-layer sponge is taken as an inner layer, a porous high-polymer material film outer layer prepared from a mixture formed by one or more of PLA (polylactic acid), PGA (polyglycolic acid), PLGA (poly(lactic-co-glycolic acid)) and PCL (polycaprolactone) is attached, the product is frozen-dried and cut, and the medical dressing with the bioactivity is formed and used for treating skin defect wounds caused by burning, scalding, operation, wounds and diseases and inducing wound repairing.

The present invention discloses a stem cell culture medium and its applications as well as a stem cell culture method. The said stem cell culture medium contains no serum. The said stem cell culture medium contains amino acids, vitamins, salts, lipids, cytokines and protein polypeptides. The said stem cell culture medium is suitable for rapid culture of stem cells derived from human and mammalian tissues, including but not limited to, adipose mesenchymal stem cells, bone marrow mesenchymal stem cells and umbilical cord blood stem cells. The said culture medium can increase the proliferation speed of the stem cells 3-5 times, without any affects on their differentiation potentials. Comparing the said stem cell culture medium to a routine culture medium, the said culture medium is not only able to proliferate stem cells derived from different sources more rapidly and achieve more proliferation generations, but also keep their differentiation potentials well.

A method of obtaining a high yield of differentiated human cells and organs includes the steps of providing typed human bone marrow or cord blood stem cells, providing pre-immune non-human mammalian fetuses, implanting the cells into the fetuses, permitting the fetuses to grow for a sufficient time to produce differentiated cells in hybrid organs, and harvesting the differentiated cells from the mammals. A method is presented to produce hybrid functioning human-animal solid organs for clinical transplantations. The method includes obtaining bone marrow mononuclear cells (BMNC) from the patient, obtaining enriched populations of HSC from the BMNC, and transplanting the enriched cells into Preimmune fetal sheep or pigs intraperitoneally to produce functioning donor (patient)-animal hybrid organs. A method is also presented in which enriched HSC isolated from pre-HLA typed normal human fetal liver/bone marrow, cord blood, or bone marrow will be transplanted into preimmune fetal sheep or pigs in order to create functioning human-animal hybrid organs that can be transplanted into compatible patients. Methods are also presented to obtain high yield of different types (e.g. hepatocytes) of donor (patient or HLA-typed normal donors) cells from the human-animal hybrid organs that can be used either for transplant into patients and/or treatment of the patient. Also disclosed is a method of producing purified human proteins that includes providing a non-human, pre-immune mammal into which human bone marrow or cord blood cells has been implanted into the mammal at the pre-immune state, obtaining blood from the non-human mammal, and isolating the human proteins from the mammalian blood.

The present invention provides a method for the collection and distribution of cord blood stem cells, particularly in order to increase the number of usable cord blood stem cells that are collected overall. By using a single collection and distribution entity that applies a uniform protocol to obtain cord blood stem cell samples at each of a plurality of different collection facilities, a greater number of samples for both private and public cord blood stem cell banks can be obtained.

Provided is a therapeutic technique for treating baldness, using an umbilical cord blood-derived stem cell. Transplantation of a composition for treating baldness into a bald area of a patient can make great contributions to treatment for baldness, wherein the composition comprises stem cells isolated and cultured from umbilical cord blood in which 6 HLA (Human Leukocyte Antigen) are identical with a patient, or one or two HLA are not identical with the patient.

The present invention relates to a method for isolating pluripotent/multipotent stem cells derived from umbilical cord blood, characterized by culturing monocytes isolated from umbilical cord blood in a culture vessel containing fibronectin and then harvesting stem cells from the culture, the umbilical cord blood-derived pluripotent/multipotent stem cells isolated thereby; and a cell therapeutic agent containing the pluripotent/multipotent stem cells derived from umbilical cord blood or cells differentiated therefrom. The present invention also relates to a novel culture media for stem cells, a culture method for stem cells which is characterized by culturing and proliferating stem cells in the culture media, and a method for increasing stemness of stem cells which is characterized by a sphere culture or a three-dimensional culture of stem cells.

The invention discloses an umbilical cord blood stem cell injection solution with an anti-aging effect and a preparation method thereof. The umbilical cord blood stem cell injection solution contains the following components by volume or concentration: 5X10<5> to 10X10<5> umbilical cord blood stem cells per ml, 2wt% of human albumin, 10-20v% of umbilical cord blood autologous plasma and 78-88v% of a compound electrolyte solution. According to the umbilical cord blood stem cell injection solution, the used stem cells are blood related stem cells and have the characteristics of amplification and directional differentiation; the cells return to an injured part when receiving an injured part signal; the cells are subjected to amplification and induced differentiation at the injured part and the stem cells of the injured part are promoted to recover functions, thereby quickly repairing and replacing injured cells and tissues; and cell factors, growth factors and tissue related factors are secreted quickly in time, thereby improving blood circulation of a human body, metabolic function, tissue repair capability and immunity, and further achieving the purpose of aging resistance.

The invention relates generally to methods for isolation and culture of umbilical cord blood stem cells, cells isolated by the methods, and therapeutic uses for those cells.

The present invention provides for enhancing engraftment by co-infusing at least two partially HLA matched umbilical cord blood (“UCB”) units. The invention further provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention further provides for enhancing the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway and that C3a and LL-37 are useful for this method. It is also disclosed herein that fragments of C3a (e.g., des-Arg) are effective in the methods of the invention, including enhancing homing of HSPCs to BM. The invention further encompasses the disclosure herein of NFAT1 regulation post-transcriptionally by both mir-184 and IFN-γ. The present invention further provides for measuring and using differences between UCB and adult CD4+/45RA+ T-cells as a means of defining strategies to enhance optimal allogeneic stem cell transplantation outcomes. The present invention further provides methods for maintaining IL-2 production in the absence of NFAT1 normal protein levels.

The invention discloses an umbilical cord blood stem cell management system. The system comprises a remote server, a terminal controller, an input apparatus, a client tracking updating module, an umbilical cord blood collection preparation module, a work station management module, a maneuvering module, an umbilical cord blood collection module, an umbilical cord blood analysis collection module, an umbilical cord blood bank management module and an integration query module. Information logging and modification can be conveniently and high-efficiently performed. Client umbilical cord blood can be ensured to be collected at first time and umbilical cord blood warehousing storage can be guaranteed. In the invention, through the umbilical cord blood collection preparation module, the work station management module, the umbilical cord blood collection module, the umbilical cord blood analysis collection module and the umbilical cord blood bank management module, a detection step and a process are optimized; detection of collected umbilical cord blood is rapid, high-efficient and timely; detection cost is greatly reduced and resource wastes are avoided.